Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.06.15.20131029: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol is in accordance with the Declaration of Helsinki and was approved by the Local Ethics Review Board of the hospitals that participated in the study.
Consent: Written informed consent was received from participants or their relatives prior to inclusion in the study.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The subjects were 25 patients hospitalized at University Hospital of Alexandroupolis or AHEPA University Hospital of Thessaloniki, with moderate (n=15), severe (n=7) or critical (n=3) COVID-19 disease (12 males, 13 females; mean age, 62.1±13.8 years; Supplemental Table S1); 10 … SciScore for 10.1101/2020.06.15.20131029: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol is in accordance with the Declaration of Helsinki and was approved by the Local Ethics Review Board of the hospitals that participated in the study.
Consent: Written informed consent was received from participants or their relatives prior to inclusion in the study.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable The subjects were 25 patients hospitalized at University Hospital of Alexandroupolis or AHEPA University Hospital of Thessaloniki, with moderate (n=15), severe (n=7) or critical (n=3) COVID-19 disease (12 males, 13 females; mean age, 62.1±13.8 years; Supplemental Table S1); 10 healthy age- and sex-matched individuals served as controls. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04395456 Not yet recruiting A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Du… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
